Supply Chain and Logistics for Cell Therapies Summit

Memo

The demand for cell and gene therapies is growing at an exponential rate as an increasing number of drug developers scale up their supply chain operations as their pipelines grow and more candidates are accelerated into the clinic. As numerous therapies progress to commercial levels, there has never been a more important time to synergize your supply and clinical efforts to future-proof the scalability, accessibility and patient-centricity of your cell or gene therapy treatment, particularly in an acute period of geopolitical global disruption. URLs:Tickets: https://go.evvnt.com/1441817-2?pid=5569 Brochure: https://go.evvnt.com/1441817-3?pid=5569  Date and Time: On Tue, 07 Mar 2023 08:00 - Thu, 09 Mar 2023 15:30 Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States Prices:Drug Developer - Conference + Focus Day: USD 4946.00,Drug Developer - Conference Only: USD 2999.00,Academic Pricing - Conference + Focus Day: USD 4246.00,Academic Pricing - Conference Only: USD 2599.00,Service Provider Pricing - Conference + Focus Day: USD 5846.00,Service Provider Pricing - Conference Only: USD 3599.00 Speakers: Akbar Mustafa, Cell and Gene Therapy, Master Data Management, Product Owner, Roche, Albert Ribickas, Cell Therapy Facility, Quality Control and Bone Marrow Transplant Manager and Supervisor, Moffitt Cancer Center, Allison Matthews, Experience Design Lead and Researcher, Service Designer, Mayo Clinic, Anuradha Mehta, Senior Director, Clinical Programs, Early Global Development, AstraZeneca, Brian Jones, Manager, CAR T Cell Collection Operations, Johnson and Johnson Services, Inc, Chris Baldwin, Senior Director, Cell and Gene Therapy Supply Chain, GlaxoSmithKline, Christian Fuchs, Head Of Orchestration and Exceptions Management ,Cell and Gene Therapy, Roche/Genentech, David Townson Oncology, Research and Development, Immuno-Oncology, Cell Therapy Executive, Bayer, Edward Armstrong, Senior Director of Quality Assurance, Mustang Bio, J.D. Mowery, Chief Operating Officer, Treadwell Therapeutics, Justin Dunlevy, Manager, Clinical Supply Chain, Precision Biosciences, Karen Moniz, Technical Director, ICCBBA, Karishma, Contractor Quality Assurance Apheresis Manager, AstraZeneca, Kellen LaVigne, Senior Manager, Cell Therapies, Sonoma Therapeutics, Lakshmi Boppana, Associate Director - Supply Chain, Vertex Pharmaceuticals, Lizette Caballero, Associate Director - Chimeric Antigen Receptor T and Apheresis Site Liasion, Jannsen of Johnson and Johnson, Pedro Rodriguez, Cardona Clinical Supply Operations Manager, Janssen of Johnson and Johnson, Rakib Ouro-Djobo, Associate Director, Clinical Supply Chain and Logistics, TCR2 Therapeutics, Robert Newman, Chief Scientific Officer, FUJIFILM Irvine Scientific, Sarah Waluda, Senior Director, Clinical Development, Autolus, Shah Ahmad, Senior Director, External Manufacturing and Supply Chain, Immunomic Therapeutics, Sumit Verma, Senior Vice President - Global Strategic Manufacturing, Iovance Biotherapeutics, Tanya Zlatanovska, Region Head of Cell and Gene Operations and Patient Support Programs, Novartis, Taylor Lundeen, Associate Director - Supply Chain, Talaris Therapeutics, Vishal Khanderia, Vice President - Supply Chain, Beam Therapeutics, William Shingler, Head of Patient and Cell Management, Autolus